- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Comparison of the Immunogenicity of five COVID-19 vaccines in Sri Lanka. (Pubmed Central) - Sep 30, 2022
The Moderna vaccine elicited the highest ACE2 blocking antibody levels followed by Sputnik V/AZD1222, while those who received Sinopharm had the lowest levels. These findings highlight the need for further studies to understand the effects on clinical outcomes.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Efficacy and safety of COVID-19 vaccination in patients with cirrhosis. (Pubmed Central) - Sep 29, 2022
These findings highlight the need for further studies to understand the effects on clinical outcomes. Vaccination against COVID-19 in patients with cirrhosis is effective and safe.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Preclinical, Journal: Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates. (Pubmed Central) - Sep 29, 2022
High immunogenic properties of the vaccine were verified in non-human primates (common marmosets) by marked IgG and neutralizing antibody (NtAb) production in blood serum, antigen-specific T-cell proliferation and cytokine release of peripheral blood mononuclear cells (PBMCs) accompanied by formation of IgA antibodies in the nasal mucosa. We also demonstrate that Sputnik V vaccine can provide sterilizing immunity in K18-hACE2 transgenic mice exposed to experimental lethal SARS-CoV-2 infection protecting them against severe lung immunopathology and mortality.We believe that intranasal Sputnik V vaccine is a promising novel needle-free mucosal vaccine candidate for primary immunization as well as for revaccination and is worth further clinical investigation.
- |||||||||| Convidecia (Adenovirus Type 5 Vector) / CanSino, NPO Petrovax, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Trial completion date, Trial primary completion date: FH-63: Phase IIB Study of Recombinant Novel Coronavirus Vaccine (clinicaltrials.gov) - Sep 29, 2022
P2b, N=450, Active, not recruiting,
We also demonstrate that Sputnik V vaccine can provide sterilizing immunity in K18-hACE2 transgenic mice exposed to experimental lethal SARS-CoV-2 infection protecting them against severe lung immunopathology and mortality.We believe that intranasal Sputnik V vaccine is a promising novel needle-free mucosal vaccine candidate for primary immunization as well as for revaccination and is worth further clinical investigation. Trial completion date: Jul 2022 --> Jan 2023 | Trial primary completion date: Jun 2022 --> Nov 2022
- |||||||||| BBIBP-CorV / Wuhan Institute of Virology, Sinopharm, Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data. (Pubmed Central) - Sep 23, 2022
P=N/A
In this national cohort of patients, the most common vaccines used were Gam-COVID-Vac and ChAdOx1 nCoV-19. A quarter of the patients presented an AE and 5.1% presented SARS-CoV-2 infection after vaccination, in most cases mild.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: The Willingness to get Vaccinated Against SARS-CoV-2 Virus among Southeast Asian Countries: Does the Vaccine Brand Matter? (Pubmed Central) - Sep 22, 2022
The current study uses data surveyed with 2,500 respondents during August and September 2021 in Vietnam, Indonesia, the Philippines and Malaysia to examine the willingness to get vaccinated against SARS-CoV-2 virus with six COVID-19 vaccines...The results indicate that additional scientific evidence on the efficacy and safety of the vaccines is essential for the respondents to decide whether to vaccinate or not. Such evidence can be made available in multiple formats and provided through appropriate channels and vaccination communication campaigns.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Experience of Military Medicine in the Fight against the New Coronavirus Infection. (Pubmed Central) - Sep 14, 2022
Among the priority scientific results of military doctors, especially noteworthy is the study of the world's first COVID-19 vaccine Sputnik V, its immunogenicity, the effectiveness of its use in previously ill patients and revaccination, as well as the use of immune plasma from those who have been ill and vaccinated...They carried out ultrastructural studies of the life cycle of the virus. It is shown that the system of comprehensive measures implemented by military medicine determined a lower incidence of new coronavirus infection among the personnel of the Ministry of Defense of Russia and a lower mortality among the military.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Plausibility of Claimed Covid-19 Vaccine Efficacies by Age: A Simulation Study. (Pubmed Central) - Sep 14, 2022
It is shown that the system of comprehensive measures implemented by military medicine determined a lower incidence of new coronavirus infection among the personnel of the Ministry of Defense of Russia and a lower mortality among the military. The distribution of alleged vaccine efficacies of the Sputnik vaccine by age in the phase-III trial is very unlikely to occur in genuine experimental data, even if the number of patients recruited, vaccine efficacy, and overall infection rate are true and there is no underlying difference in vaccine efficacy by age.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Psoriasis with Sputnik V vaccine, a potential triggering factor. (Pubmed Central) - Sep 10, 2022
The Sputnik V vaccine provided long-term and durable humoral immunity in our cohort specially if a person has been both vaccinated and had a previous infection with SARS-CoV-2. No abstract available
- |||||||||| Clinical, Review, Journal: Acute Ischemic Stroke in the Context of SARS-CoV-2 Vaccination: A Systematic Review. (Pubmed Central) - Sep 7, 2022
A systematic literature search on MEDLINE, LitCovid and LIVIVO databases was performed for eligible randomized controlled trials, observational studies, registries and case reports that reported on imaging-confirmed acute ischemic stroke in the context of any SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, Ad26.COV2.S, ChAdOx1 or Gam-COVID-Vac...In addition, differences in the likelihood of acute ischemic stroke were found among the vaccines studied, although no overall increased stroke incidence was demonstrated with vaccination. In this systematic review of the available literature, we found that the risk of acute ischemic stroke does not appear to be increased in vaccinated individuals who have received any of the currently licensed SARS-CoV-2 vaccines compared with the baseline incidence of stroke.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM. (Pubmed Central) - Sep 4, 2022
P=N/A
In this systematic review of the available literature, we found that the risk of acute ischemic stroke does not appear to be increased in vaccinated individuals who have received any of the currently licensed SARS-CoV-2 vaccines compared with the baseline incidence of stroke. we found an incidence density of breakthrough COVID-19 infection of 5 × 10.000 patients/day (95%CI 0.7-12) after vaccination in Argentina.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: SARS-CoV-2 antibodies among health care workers from a children's hospital. (Pubmed Central) - Aug 28, 2022
In Argentina, health care workers have been the first ones to receive the COVID-19 vaccine, but there are still few data on the production of anti-S IgG antibodies...Conclusion. We provide data on post-vaccination production of IgG anti-S antibodies among health care workers from a children's hospital and explore some predictors.
- |||||||||| Covaxin (BBV152 COVID Vaccine) / Bharat Biotech, Indian Council of Medical Research, Ocugen, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Observational data, Journal, Adverse events: Comparison of Side Effects of COVID-19 Vaccines: Sinopharm, AstraZeneca, Sputnik V, and Covaxin in Women in Terms of Menstruation Disturbances, Hirsutism, and Metrorrhagia: A Descriptive-Analytical Cross-Sectional Study. (Pubmed Central) - Aug 28, 2022
Seemingly, Covaxin revealed the most side effects in terms of menstruation disturbances. As a result, professionalsmust carry out several studies with reasonable samples to recommend the vaccine to those women confidently.
- |||||||||| Journal, Adverse events: Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries. (Pubmed Central) - Aug 17, 2022
P=N/A
A multicentric comparative study where SARS-CoV-2 spike 1-2 IgG antibodies IgG titers were measured at baseline, 21-28 days after the first and second dose (when applicable) of the following vaccines: BNT162b2 mRNA, mRNA-1273, Gam-COVID-Vac, Coronavac, ChAdOx1-S, Ad5-nCoV and Ad26.COV2...The delta of the antibody response only correlates with AEs in patients previously exposed to SARS-CoV-2. ClinicalTrials.gov, identifier NCT05228912.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study). (Pubmed Central) - Aug 10, 2022
VE against this outcome also showed a moderate decline over time, while booster vaccine types restored effectiveness up to almost 100%, except for the Sinopharm booster. The HUN-VE 3 study demonstrated waning VE with all vaccine types for all examined outcomes during the Delta wave and confirmed the outstanding benefit of booster vaccination with the mRNA or Janssen vaccines, and this is the first study to provide clear and comparable effectiveness results for six different vaccine types after primary immunization against severe during the Delta pandemic wave.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Vaccination Immune Response Against Sars-Cov-2 In Patients With Autoimmune Rheumatic Diseases (Screen # 1) - Aug 7, 2022 - Abstract #PANLAR2022PANLAR_149;
None of the 5 patients with Rituximab showed seroconversion...There were no differences in the serological response between patients with SLE and other rheumatic diseases. Seroconversion and antibody titres levels were associated with type of vaccine applied, being Sinopharm who presented the lowest response.
- |||||||||| BBIBP-CorV / Wuhan Institute of Virology, Sinopharm, Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Sars-Cov-2 Infection After Vaccination In Patients With Rheumatic Diseases In Argentina (Screen # 2) - Aug 7, 2022 - Abstract #PANLAR2022PANLAR_147;
At vaccination, most had low disease activity (75%) or were in remission, 19% were on steroids, 39% methotrexate, 27% bDMARDs and 6% JAK inhibitors...Only 8 vaccinated patients (12%) had an unfavorable COVID course; 7 (88%) had incomplete schemes (5 Gam-COVIDVac, 1 ChAdOx1 nCov-19 and 1 BBIBP-CorV) and one patient 2 doses of Gam-COVID-Vac...Patients with at least one vaccine dose had less frequently severe COVID-19 (12% vs 24%, p=0.067) and lower mortality rate (3% vs 6%, p=0.498). Conclusion Only 5% of patients with RD vaccinated for SARS-CoV2 had COVID-19, most mild and 25% were diagnosed after completing the scheme
- |||||||||| Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: COVID-19 cases, hospitalizations and deaths after vaccination: a cohort event monitoring study, Islamic Republic of Iran. (Pubmed Central) - Aug 6, 2022
SARS-CoV-2 Vaccine (Vero Cell) provided lower protection against COVID-19 than other vaccines. People with comorbidities had higher risks of contracting COVID-19 and hospitalization and should be prioritized for preventive interventions.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study. (Pubmed Central) - Aug 4, 2022
Thus, adjustments to the current vaccine dosing regimen are necessary to optimize immunization efficacy and cost-effectiveness. While Sputnik-V reactogenicity is similar to that of other COVID-19 vaccines, the induced alterations to the GRO/platelet axis warrant investigation of the vaccine's effects on systemic immunology.
- |||||||||| Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
Trial completion date, Trial primary completion date: The COVID-19 Back-to-Normal Study (clinicaltrials.gov) - Jul 28, 2022
P=N/A, N=1000, Recruiting,
Our results comparing between different vaccine platforms in a similar population are of great importance since they may help decision makers to adopt the best strategy for further national vaccination programs. Trial completion date: Dec 2022 --> Apr 2023 | Trial primary completion date: Jun 2022 --> Sep 2022
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Journal: SARS-CoV-2 herd immunity of the Kyrgyz population in 2021. (Pubmed Central) - Jul 27, 2022
Vaccination with Sputnik V or Sinopharm produced comparable Ab seroprevalence. SARS-CoV-2 Nag seropositivity in the Kyrgyz population was 48.75% (95% CI 47.7-49.7), with the mass vaccination campaign undoubtedly benefitting the overall situation.
- |||||||||| Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute
Review, Journal: Insights into COVID-19 vaccines development: Translation from benchside to bedside. (Pubmed Central) - Jul 23, 2022
To date, at least one dose of a COVID-19 vaccine has been received by more than 3.81 billion people worldwide, equal to about 49.7 percent of the world population. This review was written to the aim of providing a snapshot of COVID-19 disease, highlighting the well-known vaccines, and, finally understanding the effect of mix and match vaccines from different types.
|
